Pfizer (PFE) Current Deferred Tax Assets (2010 - 2026)

Pfizer (PFE) has reported Current Deferred Tax Assets for 17 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Tax Assets fell 7.82% year-over-year to $3.7 billion in Q2 2026; TTM through Jun 2026 was $3.7 billion, a 7.82% decrease from a year earlier, with the FY2025 full-year figure at $4.0 billion, up 19.7% from the prior year.
• Current Deferred Tax Assets was $3.7 billion for Q2 2026 at Pfizer, up from $3.6 billion in the prior quarter.
• Over five years, Current Deferred Tax Assets peaked at $4.2 billion in Q1 2024 and troughed at $2.6 billion in Q3 2022.
• A 5-year average of $3.5 billion and a median of $3.6 billion in 2022 frame the typical range for Current Deferred Tax Assets.
• Across the five-year window, Current Deferred Tax Assets soared 34.81% in 2024 and tumbled 31.49% in 2025, its largest moves.
• Over 5 years, Current Deferred Tax Assets stood at $3.6 billion in 2022, then climbed by 11.21% to $4.0 billion in 2023, then dropped by 16.69% to $3.3 billion in 2024, then gained by 19.7% to $4.0 billion in 2025, then slipped by 6.68% to $3.7 billion in 2026.
• The last three Current Deferred Tax Assets figures came in at $3.7 billion (Q2 2026), $3.6 billion (Q1 2026), and $4.0 billion (Q4 2025), per Business Quant data.